Table 3.
Previous Studies |
Current Study N= 138 White, ≥ 37 weeks |
||||||||
---|---|---|---|---|---|---|---|---|---|
CP | Gest | Demo- | CP | Rare Homozygote vs. Common Homozygote |
Heterozygote vs. Common Homozygote |
CP | Rare Homozygote vs. Common Homozygote |
Heterozygote vs. Common Homozygote* |
|
Gene (codon) | (N ) |
Age (wk) |
graphics | Typ e** |
OR (95% CI) | OR (95% CI) | Typ e |
OR (95% CI) | OR (95% CI) |
Inflammatory | |||||||||
TNF-alpha -308 (8) | 65 | ≥ 37 | Whites | QP | 0.0 (0.0–1.6) | 1.8 (1.04–3.2) | All | 1.9 (0.4–8.0) | 0.8 (0.5–1.3) |
IL-8 -251 (6) | 153 | < 37 | Whites | All | 2.4 (1.3–4.4) | 2.0 (1.2–3.5)† | All | 1.3 (0.7–2.5) | 1.1 (0.7–1.9) |
121 | All | Whites | DP | 0.8 (0.5–1.3)† | 1.9 (1.2–3.1) | DP | 1.7 (0.6–4.9) | 1.5 (0.6–3.9) | |
Lymphtotoxin 60 (6, 11) | 356 | All | Whites | All | 1.5 (1.01–2.18) | 1.2 (0.9–1.6)† | All | 1.3 (0.6–2.7) | 0.8 (0.5–1.3) |
118 | All | Whites | HP | 1.8 (1.02–3.23) | 1.3 (0.9–2.1)† | HP | 0.9 (0.3–1.4) | 0.6 (0.3–1.2) | |
110 | All | Whites | QP | 1.9 (1.01–3.3) | 1.5 (0.9–2.4)† | QP | 1.5 (0.5–4.4) | 1.0 (0.5–2.1) | |
96 | <32 | Whites, Hispanics | All | 0.4 (0.1–1.2)† | 1.4 (0.8–2.6)† | DP | 1.6 (0.5–4.8) | 0.9 (0.4–2.0) | |
eNOS -922 (6, 11) | 96 | <32 | Whites, Hispanics | All | 0.5 (0.1–1.6)† | 2.2 (1.2–4.0)† | All | 1.4 (0.7–2.9) | 0.9 (0.6–1.5) |
126 | All | Whites | DP | 0.5 (0.3–0.95) | 0.7 (0.5–1.1)† | DP | 1.7 (0.6–5.0) | 0.7 (0.3–1.6) | |
iNOS -231 (6) | 180 | ≥ 37 | Whites | All | 0.9 (0.5–1.7)† | 1.6 (1.1–2.2) | All | 1.01 (0.3–3.7) | 1.9 (1.2–3.1) |
EPCR 219 (6) | 190 | ≥ 37 | Whites | All | 0 (0–2.3)† | 1.6 (1.1–2.3) | All | 1.2 (0.2–8.5) | 0.9 (0.5–1.6) |
127 | All | Whites | DP | 0.9 (0.02–6.4)† | 1.9 (1.2 – 3.1) | DP | 2.4 (0.2–27.1) | 0.8 (0.3–2.2) | |
MBL 54 (8) | 49 | All | Whites | DP | 0.7 (0.1–3.2) | 1.6 (1.1–2.4) | All | 2.8 (0.5–15.0) | 0.7 (0.4–1.3) |
21 | ≥ 37 | Whites | DP | 1.2 (0.03–8.1) | 2.2 (1.1–4.2) | DP | 2.2 (0.2–25.3) | 0.6 (0.2–1.5) | |
MBL 52 (8) | 65 | ≥ 37 | Whites | QP | 0 (0–18.8) | 3.8 (1.03–11.1) | All | 1.2 (0.1–18.9) | 0.9 (0.4–1.7) |
Thrombotic | |||||||||
FVL (506) | 1 | NA | NA‡ | HP | NA | NA | All | - | 0.8 (0.4–1.8) |
MTHFR 677 (10) | 58 | 32–36 | Whites | All | 2.6 (1.1–5.7) | 1.9 (1.01–3.7) | All | 0.4 (0.2–0.9) | 0.6 (0.4–1.04) |
58 | < 32 | Whites | DP | 2.8 (1.2–6.1) | 1.6 (1.02–2.5) | DP | 0.5 (0.1–2.0) | 0.8 (0.4–1.7) | |
MTHFR 1298 (10) | 20 | 32–36 | Whites | DP | 0.5 (0.1–2.3) | 0.2 (0.02–0.07) | All | 0.6 (0.7–3.8) | 0.3 (0.8–2.0) |
Prothrombin 20210 (10) | 20 | 32–36 | Whites | DP | 0 (0.0–67.5) | 4.3 (0.8–16.6)†§ | All | - | 0.5 (0.1–2.1) |
PAI-1 11053 (6) | 150 | All | White Girls | All | 1.9 (1.1–3.4) | 1.6 (0.9–2.6)† | All | 1.0 (0.5–2.0) | 1.2 (0.7–2.1) |
Apolipoprotein E | |||||||||
ε4 allele (15, 16) | 209 | All | White, Hispanic, black | All | 2.9 (0.5–30.8)† | 3.4 (1.4–8.7) | All | 1.6 (0.5–5.6) | 1.7 (1.01–2.9) |
40 | All | Brazilian | All | Unknown | 5.8 (1.3–34.8)† | HP | 2.1 (0.5–9.1) | 1.9 (0.96–3.8) | |
ε2 allele (16–18) | 209 | All | White, Hispanic, black | All | Unknown | 12.0 (1.6–247) | All | - | 1.1 (0.6–2.1) |
106 | <32 | Whites | All | Unknown | 3.5 (1.1–12.7) | HP | - | 1.3 (0.6–3.1) | |
243 | All | Brazilian | All | Unknown | 2.8 (1.01–7.66) | DP | - | 1.2 (0.4–3.6) |
Note that none of the genetic associations were statistically significant after adjusting for multiple comparisons. Due to space constraints, this table does not include dominant genetic analyses (i.e. rare homozygote or heterozygote, compared to common homozygote). We found no significant associations when data were analyzed with dominant genetic comparisons.
DP = diplegic, HP = hemiplegic, QP = quadriplegic, All = DP + HP + QP. Note that when a polymorphism was not associated with overall CP, there was similarly no association found between that polymorphism and any subtype of CP.
These OR's were calculated from the raw data provided in published papers.
NA = not available. An association between FVL and CP has only been reported in case reports and case series, and therefore no risk ratios are available.
The controls used in this calculation were term infants ≥ 37 weeks gestation.